Plexxikon Files for Approval of Highly Touted Melanoma Drug
By Jennifer Boggs
Thursday, May 12, 2011
A mere four and a half years after launching clinical development, Plexxikon Inc. filed marketing applications in the U.S. and Europe for its targeted melanoma drug PLX4032, now known as vemurafenib.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.